File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)

Article: Treatment of knee osteoarthritis with Lyprinol®, lipid extract of the green-lipped mussel - A double-blind placebo-controlled study

TitleTreatment of knee osteoarthritis with Lyprinol®, lipid extract of the green-lipped mussel - A double-blind placebo-controlled study
Authors
KeywordsChronic osteoarthritis
Essential fatty acids
Lyprinol®
Natural remedies
Perna canaliculus
Quality of life
Issue Date2004
PublisherMattioli 1885 SpA.
Citation
Progress In Nutrition, 2004, v. 6 n. 1, p. 17-31 How to Cite?
AbstractTreatment of osteoarthritis (OA) includes pain control and improvement of patients' function and quality of life. While conventional treatment such as non-steroidal anti-inflammatory drugs and simple analgesics may achieve these goals, their use is not without side-effects. The use of "natural remedies" and "folklore medicines" is therefore commonly practised by patients with OA. Lyprinol® is a lipid extract of the green-lipped mussel which is rich in omega-3 fatty acids and has previously been shown to have anti-inflammatory effects in both in vitro and animal studies. The aim of this study was to compare the effects of Lyprinol® with placebo on the signs and symptoms and patient quality of life in the treatment of knee OA. Eighty patients with knee OA were randomized to receive either Lyprinol® or placebo for six months. All were allowed paracetamol rescue treatment during the study and were reviewed at week 0, 2, 4, 8, 12, 18 and 24 for arthritis assessment and safety evaluation. Assessment of the patients' arthritis included the use of a 100 mm visual analog scale (VAS) for pain, patient's and physician's global assessment of arthritis, a validated Chinese version of the Oxford Knee Score (COKS), a validated Chinese version of the Arthritis Impact Measurement Scale 2-short form (CAIMS2-SF), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Improvement in almost all of the arthritis assessment parameters was observed in both groups of patients studied. However, there was a greater improvement in the perception of pain as measured by the VAS, and patients' global assessment of arthritis in those who took Lyprinol® when compared with controls from week 4 following adjustment for the change in the amount of paracetamol used between study visits. Patients who took Lyprinol® but not placebo also had improved scores in the CAIMS2-SF physical function and psychological status domains from week 4. However, changes in these scores did not differ significantly between the two groups at various study visits. When used over six months, Lyprinol® was safe and well tolerated with no serious side-effects reported. Further, there were no significant differences in the overall incidence of adverse reactions or withdrawal from study as a result of trial drug toxicity between Lyprinol® and placebo treated patients. In conclusion, Lyprinol®, a lipid extract of the green-lipped mussel, may be considered a safe option in the treatment of OA.
Persistent Identifierhttp://hdl.handle.net/10722/79430
ISSN
2015 Impact Factor: 0.312
2015 SCImago Journal Rankings: 0.170
References

 

DC FieldValueLanguage
dc.contributor.authorLau, CSen_HK
dc.contributor.authorChiu, PKYen_HK
dc.contributor.authorChu, EMYen_HK
dc.contributor.authorCheng, IYWen_HK
dc.contributor.authorTang, WMen_HK
dc.contributor.authorMan, RYKen_HK
dc.contributor.authorHalpern, GMen_HK
dc.date.accessioned2010-09-06T07:54:35Z-
dc.date.available2010-09-06T07:54:35Z-
dc.date.issued2004en_HK
dc.identifier.citationProgress In Nutrition, 2004, v. 6 n. 1, p. 17-31en_HK
dc.identifier.issn1129-8723en_HK
dc.identifier.urihttp://hdl.handle.net/10722/79430-
dc.description.abstractTreatment of osteoarthritis (OA) includes pain control and improvement of patients' function and quality of life. While conventional treatment such as non-steroidal anti-inflammatory drugs and simple analgesics may achieve these goals, their use is not without side-effects. The use of "natural remedies" and "folklore medicines" is therefore commonly practised by patients with OA. Lyprinol® is a lipid extract of the green-lipped mussel which is rich in omega-3 fatty acids and has previously been shown to have anti-inflammatory effects in both in vitro and animal studies. The aim of this study was to compare the effects of Lyprinol® with placebo on the signs and symptoms and patient quality of life in the treatment of knee OA. Eighty patients with knee OA were randomized to receive either Lyprinol® or placebo for six months. All were allowed paracetamol rescue treatment during the study and were reviewed at week 0, 2, 4, 8, 12, 18 and 24 for arthritis assessment and safety evaluation. Assessment of the patients' arthritis included the use of a 100 mm visual analog scale (VAS) for pain, patient's and physician's global assessment of arthritis, a validated Chinese version of the Oxford Knee Score (COKS), a validated Chinese version of the Arthritis Impact Measurement Scale 2-short form (CAIMS2-SF), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Improvement in almost all of the arthritis assessment parameters was observed in both groups of patients studied. However, there was a greater improvement in the perception of pain as measured by the VAS, and patients' global assessment of arthritis in those who took Lyprinol® when compared with controls from week 4 following adjustment for the change in the amount of paracetamol used between study visits. Patients who took Lyprinol® but not placebo also had improved scores in the CAIMS2-SF physical function and psychological status domains from week 4. However, changes in these scores did not differ significantly between the two groups at various study visits. When used over six months, Lyprinol® was safe and well tolerated with no serious side-effects reported. Further, there were no significant differences in the overall incidence of adverse reactions or withdrawal from study as a result of trial drug toxicity between Lyprinol® and placebo treated patients. In conclusion, Lyprinol®, a lipid extract of the green-lipped mussel, may be considered a safe option in the treatment of OA.en_HK
dc.languageengen_HK
dc.publisherMattioli 1885 SpA.en_HK
dc.relation.ispartofProgress in Nutritionen_HK
dc.subjectChronic osteoarthritisen_HK
dc.subjectEssential fatty acidsen_HK
dc.subjectLyprinol®en_HK
dc.subjectNatural remediesen_HK
dc.subjectPerna canaliculusen_HK
dc.subjectQuality of lifeen_HK
dc.titleTreatment of knee osteoarthritis with Lyprinol®, lipid extract of the green-lipped mussel - A double-blind placebo-controlled studyen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1129-8723&volume=6&issue=1&spage=17&epage=31&date=2004&atitle=Treatment+of+knee+osteoarthritis+with+Lyprinol,+lipid+extract+of+the+green-lipped+mussel+-+a+double-blind+placebo-controlled+studyen_HK
dc.identifier.emailLau, CS: cslau@hku.hken_HK
dc.identifier.emailChiu, PKY: pkychiu@hkucc.hku.hken_HK
dc.identifier.emailMan, RYK: rykman@hkucc.hku.hken_HK
dc.identifier.authorityLau, CS=rp01348en_HK
dc.identifier.authorityChiu, PKY=rp00379en_HK
dc.identifier.authorityMan, RYK=rp00236en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.scopuseid_2-s2.0-4344649981en_HK
dc.identifier.hkuros100581en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-4344649981&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume6en_HK
dc.identifier.issue1en_HK
dc.identifier.spage17en_HK
dc.identifier.epage31en_HK
dc.publisher.placeItalyen_HK
dc.identifier.scopusauthoridLau, CS=14035682100en_HK
dc.identifier.scopusauthoridChiu, PKY=7202988127en_HK
dc.identifier.scopusauthoridChu, EMY=7102620368en_HK
dc.identifier.scopusauthoridCheng, IYW=7102537490en_HK
dc.identifier.scopusauthoridTang, WM=7403430820en_HK
dc.identifier.scopusauthoridMan, RYK=7004986435en_HK
dc.identifier.scopusauthoridHalpern, GM=7005514590en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats